NeuroSense Therapeutics Ltd. (NRSN)
| Market Cap | 22.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.11M |
| Shares Out | 18.04M |
| EPS (ttm) | -0.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,507,300 |
| Open | 1.090 |
| Previous Close | 1.080 |
| Day's Range | 1.070 - 1.500 |
| 52-Week Range | 0.400 - 2.330 |
| Beta | 1.53 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+504.84%) |
| Earnings Date | Aug 14, 2024 |
About NRSN
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under pr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NRSN stock is "Strong Buy" and the 12-month stock price forecast is $7.5.
News
This cheap biotech offers investors a play on ALS if trial data continues to impress
NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug
Disease progression was slowed by 36% (p=0.009) in participants who received PrimeC for 12 months compared to those who initially received a placebo Consistent data across multiple endpoints underscor...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results
Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term CAMBRIDGE, Mass. , June 24, 2024 /PRN...
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
CAMBRIDGE, Mass. , June 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit
CAMBRIDGE, Mass. , May 20, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
PhaseV's Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense's Phase 3 Trial CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- NeuroSense Therapeutics (...
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patients Consistent data across subgroups underscore the potential of PrimeC to redefine the ALS treatment paradigm CAM...
NeuroSense Announces First Quarter 2024 Business Update
CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
CAMBRIDGE, Mass. , April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consistent trend toward impact on Neurofilament biomarker levels CAMBRIDGE, Mass....
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes CAMBRIDGE, Mass. , April 12, 2024 /PRNewswire/ -- NeuroSense Therapeutics ...
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
CAMBRIDGE, Mass. , April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field Lonza to develop, optimize, and qualify a method util...
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
CAMBRIDGE, Mass. , April 5, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS Standard ALS Measure ALSFRS-R already demonstrated a statistically signifi...
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
CAMBRIDGE, Mass. , Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
HERZLIYA, ISRAEL / ACCESSWIRE / January 30, 2024 / Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. I...
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussions CAMBRIDGE, Mass. , ...
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
This notification has no immediate effect on the listing or trading of NeuroSense's ordinary shares on the Nasdaq Capital Market CAMBRIDGE, Mass. , Dec. 27, 2023 /PRNewswire/ -- NeuroSense Therapeutic...
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol (PP) populat...
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense's lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a safe...
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
Data to be announced in a premarket press release followed by a conference call at 8:30 am ET CAMBRIDGE, Mass. , Dec. 4, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early December 2023 Patients who completed the 18-month PARADIGM trial, includin...
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
- Last patient completed the double-blind segment of PARADIGM, a Phase 2b ALS Trial - Clinical efficacy top-line results from PARADIGM expected in December 2023 CAMBRIDGE, Mass. , Nov. 9, 2023 /PRNews...